Collagenase clostridium histolyticum is a type of enzyme formed by the bacterium clostridium histolyticum that helps in the breakdown of collagen. It is majorly used in the treatment of Dupuytren’s contracture, a medical condition where the fingers of the patient bend towards the palm due to the formation of knots under the skin. The collagenase clostridium histolyticum market is expected witnessed a remarkable growth due to the high prevalence of Dupuytren’s contracture across the major geographies of the world. Moreover, increasing applicability of collagenase clostridium histolyticum in other medical indications such as wound care and Peyronie’s disease market will drive the growth of the market in the near future.
This Report Gives Readers a Comprehensive Overview of Collagenase Clostridium Histolyticum Market: http://www.transparencymarketresearch.com/collagenase-clostridium-histolyticum-market.html
Some of the major medications based on collagenase clostridium histolyticum are as follows:
> XIAFLEX (U.S.)
> Xiapex (Europe)
> Collagenase SANTYL
Some of the side-effects often experienced by individuals after receiving collagenase are as follows:
Blisters at the injection site
> Itching of the treated hand
> Painful erection
> Painful sexual activity
> Swollen and painful glands in the underarm or elbow area
In terms of geographical analysis, North America followed by Europe account for the largest market share of collagenase clostridium histolyticum due to the high prevalence Dupuytren’s disease and Peyronie’s disease in the U.S. Since, the major application of collagenase clostridium histolyticum lies in Dupuytren’s disease, occurrence of this disease is the key factor behind the growth of this market. According to various scientific studies, the prevalence of Dupuytren’s disease in the U.S. is around 4%; moreover, this disease is most often diagnosed in Caucasians of Northern European origin. However, the prevalence of Dupuytren’s disease is sporadic in regions such as Asia and Africa. Hence, the market for collagenase clostridium histolyticum is expected to prosper more in developed regions such as North America and Europe as compared to other regions such as Asia and Africa.
The global collagenase clostridium histolyticum market is witnessing an admirable growth due to the growing prevalence of Dupuytren’s contracture and Peyronie’s disease, increasing usage of collagenase in various medical areas such as wound care, pain management, etc. Furthermore, increasing usage of collagenase based products in the burn management and necrotic tissue management are expected to boost the growth of overall collagenase clostridium histolyticum market in the near future. Moreover, due to the lack of other standard medicines and therapies for treating Dupuytren’s contracture and Peyronie’s disease, this market is expected to grow at an appreciable pace. Additionally, increasing number of clinical studies focused on finding other applications of collagenase in human healthcare are expected to amplify the growth of collagenase clostridium histolyticum market in developed nations. However, stringent regulatory approval policies of collagenase and high pricing are few of the important factors that might act as hindrances for the growth of this market.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving Collagenase Clostridium Histolyticum Market by 2023: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4474
The global collagenase clostridium histolyticum market is highly competitive and consolidated due to the participation and presence of a few major players in this market. The market is expected to witness a steady growth rate due to the increasing prevalence of Dupuytren’s disease and Peyronie’s disease in developed nations such as the U.S, the U.K. and Spain. Some of the major companies involved in the manufacturing and commercialization of collagenase clostridium histolyticum are Auxilium Pharmaceuticals, Inc., BioSpecifics Technologies Corp., Smith & Nephew plc and Swedish Orphan Biovitrum AB (publ), amongst others.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453